| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2019 ( Subtotal = -$1,000,000 ) |
| | 2019 | 2018 | ATRAPOS THERAPEUTICS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44AI125007 | Preclinical evaluation of a novel small molecule STAT inhibitor | 000 | 2 | NIH | 12/24/2018 | -$1,000,000 |
|
| Issue Date FY: 2018 ( Subtotal = $1,000,000 ) |
| | 2018 | 2018 | ATRAPOS THERAPEUTICS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R44AI125007 | Preclinical evaluation of a novel small molecule STAT inhibitor | 000 | 2 | NIH | 8/20/2018 | $1,000,000 |
| | 2018 | 2016 | ATRAPOS THERAPEUTICS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R41AI125007 | STAT Inhibitors for Asthma Therapy | 000 | 1 | NIH | 5/3/2018 | $0 |
|
| Issue Date FY: 2016 ( Subtotal = $227,537 ) |
| | 2016 | 2016 | ATRAPOS THERAPEUTICS, LLC | 3900 ESSEX LN STE 575 | HOUSTON | TX | 77027-5175 | HARRIS | USA | R41AI125007 | STAT Inhibitors for Asthma Therapy | 000 | 1 | NIH | 7/27/2016 | $227,537 |
|
|
